FBLG NASDAQ
FibroBiologics, Inc. Common Stock
1W: -1.8%
1M: -29.4%
3M: +328.4%
YTD: +350.2%
1Y: +15.6%
$1.08
-0.01 (-0.92%)
Weekly Expected Move ±12.9%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.3M
52W Range0.952-19.8
Volume120,524
Avg Volume445,232
Beta1.10
Dividend—
Analyst Ratings
Company Info
CEOPeter O'Heeron
Employees13
SectorHealthcare
IndustryBiotechnology
IPO Date2024-02-01
Websitefibrobiologics.com
455 East Medical Center Boulevard
Houston, DE 77598
US
Houston, DE 77598
US
281 651 5150
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Latest News
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study
FibroBiologics reports Q1 results
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| O'HEERON PETE | A-Award | 92,410 | $1.38 | 2026-05-04 |
| Khoja Hamid | A-Award | 61,607 | $1.38 | 2026-05-04 |
| Davis Jason | A-Award | 61,607 | $1.38 | 2026-05-04 |
| GARCIA RUBEN A | A-Award | 61,607 | $1.38 | 2026-05-04 |
| Khoja Hamid | P-Purchase | 30,000 | $0.38 | 2026-03-04 |